Treatment-related neuroendocrine prostate cancer resulting in Cushing's syndrome

2016 ◽  
Vol 23 (12) ◽  
pp. 1038-1041 ◽  
Author(s):  
Sundhar Ramalingam ◽  
Adva Eisenberg ◽  
Wen Chi Foo ◽  
Jennifer Freedman ◽  
Andrew J Armstrong ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome ◽  
Neuroendocrine Prostate Cancer

Paraneoplastic Cushing’s syndrome in prostate cancer: a difficult management problem

2007 ◽  
Vol 101 (4) ◽  
pp. 424-427 ◽  
Author(s):  
Samantha Nimalasena ◽  
Alex Freeman ◽  
Stephen Harland
Keyword(s):  
Prostate Cancer ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome ◽  
Management Problem

scholarly journals Ectopic Cushing’s From Metastatic Prostate Cancer

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A757-A757
Author(s):  
Zachary Bloomer ◽  
Jennifer Teague ◽  
Nicole Vietor
Keyword(s):  
Prostate Cancer ◽  
Cushing’S Syndrome ◽  
Metastatic Prostate Cancer ◽  
Systemic Chemotherapy ◽  
Bronchial Carcinoma ◽  
Cushing's Syndrome ◽  
Ectopic Acth ◽  
Ectopic Acth Production ◽  
Urine Cortisol ◽  
Castrate Resistant

Abstract Objective: Ectopic ACTH production from malignancy is a rare etiology of Cushing’s syndrome. The most common tumors associated with this syndrome include small cell lung cancer, pancreatic neuroendocrine tumors, pheochromoctoma, thymic carcinoma, and bronchial carcinoma. Metastatic prostate cancer does not commonly produce ACTH. Here, we present a rare case of Cushing’s syndrome due to metastatic prostate cancer. Case Report: Patient is a 64 year old man with a 2 year history of castrate-resistant prostate cancer who was admitted for the 2nd time in 1 month for profound weakness and new onset hypokalemia. Initial analysis revealed hypertension with systolic blood pressure in the 150s, potassium in the mid 2s, an ACTH level of >1000pg/mL, and a 24-hr urine cortisol of almost 10,000mcg/24hrs. This was confirmed on repeat analysis. Metyrapone was initiated for treatment of hypercortisolemia and systemic chemotherapy with Cisplatin/Irinotecan was started to treat metastatic prostate cancer. ACTH and 24-hr urine cortisol levels returned to normal within a few weeks of therapy. The patient was able to discontinue Metyrapone following systemic chemotherapy treatment. Subsequent labs following discontinuation of metyrapone confirmed ongoing resolution of hypercortisolemia. Conclusion: This case represents an extremely rare cause of Cushing’s syndrome. Metastatic prostate cancer can rarely produce ACTH and cause clinical Cushing’s syndrome. Ectopic Cushing’s syndrome is often due to very aggressive tumors and is associated with a poor prognosis. Rapid recognition and treatment of this condition can be lifesaving.

Cushing’s Syndrome in Prostate Cancer

1999 ◽  
Vol 63 (2) ◽  
pp. 126-129 ◽  
Author(s):  
Svein Andreas Haukaas ◽  
Ole Johan Halvorsen ◽  
Svein Jacob Tjoflaat Nygaard ◽  
Elisabeth Paus
Keyword(s):  
Prostate Cancer ◽  
Cushing’S Syndrome ◽  
Cushing's Syndrome

scholarly journals MON-317 Ectopic Cushing's Syndrome Due to Prostate Cancer: A Case Series

2019 ◽  
Vol 3 (Supplement_1) ◽  
Author(s):  
Sarah Kanbour ◽  
Rebecca Braunstein ◽  
Avani Sinha ◽  
Susan Slovin ◽  
Eliza Geer
Keyword(s):  
Prostate Cancer ◽  
Cushing’S Syndrome ◽  
Case Series ◽  
Cushing's Syndrome ◽  
Ectopic Cushing’S Syndrome
Sign in / Sign up

Export Citation Format

Share Document